Sign In
Buy SGMO
$0.0740
+0 (+0%)
At Close: Jul 13, 2026
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
08:05am, Tuesday, 23'rd Jun 2026
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalki
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
08:05am, Monday, 08'th Jun 2026
RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the comp
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
06:30pm, Thursday, 14'th May 2026
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
06:17pm, Thursday, 14'th May 2026
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago.
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
04:01pm, Thursday, 14'th May 2026
Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-50
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
08:05am, Wednesday, 29'th Apr 2026
RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Na
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
06:22pm, Monday, 30'th Mar 2026
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
04:01pm, Monday, 30'th Mar 2026
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al
Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
04:07am, Monday, 30'th Mar 2026
Sangamo Therapeutics will release Q4 earnings on March 30. Analysts predict a quarterly loss of 5 cents per share and revenue of $40.25 million.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
04:03pm, Thursday, 19'th Mar 2026
RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quar
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
08:05am, Monday, 09'th Mar 2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally s
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
04:05pm, Tuesday, 03'rd Feb 2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally s
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
09:10am, Tuesday, 03'rd Feb 2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
08:05am, Thursday, 18'th Dec 2025
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ha
